about
HDAC Inhibitors as Epigenetic Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory DiseasesProgress in epigenetic histone modification analysis by mass spectrometry for clinical investigationsLysine deacetylase (KDAC) regulatory pathways: an alternative approach to selective modulationEpigenetic plasticity: a central regulator of epithelial-to-mesenchymal transition in cancerEpigenetic modulators as therapeutic targets in prostate cancerInhibition of BET bromodomains as a therapeutic strategy for cancer drug discoveryInhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphomaIdentification of Epigenetic Biomarkers of Lung Adenocarcinoma through Multi-Omics Data AnalysisSafety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II studyMelittin restores PTEN expression by down-regulating HDAC2 in human hepatocelluar carcinoma HepG2 cells.Advances in epigenetic glioblastoma therapy.B1, a novel HDAC inhibitor, induces apoptosis through the regulation of STAT3 and NF-κB.Histone deacetylase inhibition modulates histone acetylation at gene promoter regions and affects genome-wide gene transcription in Schistosoma mansoniHDAC5 controls the functions of Foxp3(+) T-regulatory and CD8(+) T cellsHDAC4: mechanism of regulation and biological functionsEffects of 5-aza-2'-deoxycytidine and trichostatin A on high glucose- and interleukin-1β-induced secretory mediators from human retinal endothelial cells and retinal pigment epithelial cellsDecreased expression of histone deacetylase 10 predicts poor prognosis of gastric cancer patients.Small-molecular modulators of cancer-associated epigenetic mechanisms.The Histone Deacetylase Inhibitor Trichostatin A Sensitizes Human Renal Carcinoma Cells to TRAIL-Induced Apoptosis through Down-Regulation of c-FLIPL.The conserved histone deacetylase Rpd3 and its DNA binding subunit Ume6 control dynamic transcript architecture during mitotic growth and meiotic development.The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells.Antioxidants impair anti-tumoral effects of Vorinostat, but not anti-neoplastic effects of Vorinostat and caspase-8 downregulationProportions of acetyl-histone-positive hepatocytes indicate the functional status and prognosis of cirrhotic patientsNovel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor responseConnectivity mapping using a combined gene signature from multiple colorectal cancer datasets identified candidate drugs including existing chemotherapiesHDAC9 promotes glioblastoma growth via TAZ-mediated EGFR pathway activation.Targeting Histone Deacetylases in Diseases: Where Are We?HDAC Family Members Intertwined in the Regulation of Autophagy: A Druggable Vulnerability in Aggressive Tumor Entities.Reactivation of epigenetically silenced miR-512 and miR-373 sensitizes lung cancer cells to cisplatin and restricts tumor growth.Dual targeting of retinoid X receptor and histone deacetylase with DW22 as a novel antitumor approach.Potential anti-cancer effect of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a novel histone deacetylase inhibitor, for the treatment of thyroid cancer.Transmembrane protein 88 (TMEM88) promoter hypomethylation is associated with platinum resistance in ovarian cancerTumor suppression by MEG3 lncRNA in a human pituitary tumor derived cell line.Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma.Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis.Human papillomavirus type 16 E7 oncoprotein mediates CCNA1 promoter methylation.MicroRNA miR124 is required for the expression of homeostatic synaptic plasticity.KLF4 regulates adult lung tumor-initiating cells and represses K-Ras-mediated lung cancer.The phosphorylated prodrug FTY720 is a histone deacetylase inhibitor that reactivates ERα expression and enhances hormonal therapy for breast cancer.The rise of epigenetic targets for the development of novel antivirals
P2860
Q26739120-3DB916C7-DB14-44D2-89D0-F9E1F7E07E39Q26781745-DD3B53EB-25AD-4531-B790-C7B823B5BDA3Q27021965-4D7BDA28-4534-49AF-B522-A3C840C33AAFQ27022720-5031C8B8-D79B-4E6F-82BB-974DDCEBAEB6Q28071912-7C8B5B11-E475-4D0D-85DF-0E18C012221FQ28260105-C0A01D7D-01E9-4D65-8EE5-8A0312912C84Q28534761-E407F293-C3AE-4CB0-AA94-543CE8591D7BQ31068011-C770B919-3103-4F0F-B3BA-C293FEFF7200Q33438732-D04017E3-748E-4E29-A5A1-6AC8D963BF55Q33559887-C34D34FA-F12B-4721-BC33-F640A79CD0B4Q33567030-D18C9FFC-7874-43D6-95C6-250CDB6DD604Q33597695-30B093EB-C40C-481D-B9A8-404D2B198429Q33602816-4ADC4CDA-0ABE-47CF-A94D-57AC9241711AQ33834432-206512B7-FC78-4162-9E5E-379BE009D080Q34039987-DB72B234-6208-4459-AF62-8B467A45D964Q34249929-6C113A54-C5C9-446E-8741-C61FB0114DC4Q34371426-5FCD0D10-9298-44BC-8840-FE2735C2F9AFQ34628002-A7372CBA-67BC-4D5B-BAF1-D62E19A3E41AQ34865077-8B18896B-D0F7-4E52-A056-177E7F05CB94Q34882908-9F0A10BC-0A8B-485B-A242-E25B4F292BB1Q35052701-C3F303D0-B584-43BE-BA8A-373F5FE76E4DQ35126359-A4AF5BD5-F07F-4181-9777-50C4F882BA33Q35692323-743C61AE-314F-4EF8-B9EF-3271B63138B9Q35741605-723DB9A0-4E3C-44EA-9EBD-E826F083FA21Q35769403-29D90FDE-95B4-413C-9873-299C0317B9ECQ35781376-E3FE1A62-B729-4BCA-8B71-4EFCBB070E43Q35821728-8089E314-B790-48F6-AEFD-7521B770871AQ35824343-5785F9B4-4500-406F-A9A8-F04768637B8FQ35829861-927E532C-F1A9-473E-B622-09DE8D9758E6Q35833127-3F907553-49FA-4582-A70E-B387708E9E5CQ35876617-6967A289-53DC-43D7-B676-FF29EB044306Q36067023-11636F67-8E28-4575-BC0C-CB67E7EDA0C8Q36161900-17E0D8DE-5A75-4A7A-8A3C-C61D4B68684DQ36214527-199D2892-BAAD-440A-8A53-164BE39BB409Q36256343-8175D36F-47DA-4866-936B-79C277C47E4FQ36262957-3F7E5EE1-20DB-4673-A3F6-CB639B633DC7Q36392115-C2B26853-3A72-42AE-985C-1505C679ED5CQ36472473-7C08C2D1-E633-43E5-B5F8-F057B2BE6391Q36579794-278E3715-4FA8-4000-B368-7A577620FBD4Q36657906-39CCFE97-9698-4862-BD86-8090F4A31C84
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
Histone deacetylases and cancer.
@ast
Histone deacetylases and cancer.
@en
Histone deacetylases and cancer.
@nl
type
label
Histone deacetylases and cancer.
@ast
Histone deacetylases and cancer.
@en
Histone deacetylases and cancer.
@nl
prefLabel
Histone deacetylases and cancer.
@ast
Histone deacetylases and cancer.
@en
Histone deacetylases and cancer.
@nl
P2860
P1433
P1476
Histone deacetylases and cancer
@en
P2093
Bruna Barneda-Zahonero
P2860
P304
P356
10.1016/J.MOLONC.2012.07.003
P577
2012-08-27T00:00:00Z